e-ESO Podcasts

Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Expert: Sabrina Kahler Ribeiro Fontana, European Institute of Oncology, Milan, Italy

Expert: Nicola Fusco, University of Milan and IRCCS European Institute of Oncology, Milan, IT

Expert: Maggie Banys Paluchowski, University Hospital Schleswig-Holstein (UKSH), Lübeck, DE Questions: 1-Why do we need localization techniques? 2-How to perform intraoperative ultrasound? 3-Can you comment on the available evidence on intraoperative ultrasound? 4-What can be potential problems of intraoperative ultrasound? 5-What about intraoperative ultrasound in palpable lesions?

Expert: Luca Bertolaccini , Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Expert: Erick Figueiredo Saldanha, AC Camargo Cancer Center, Sao Paulo, Brazil

Expert Ramon Andrade Bezerra de Mello, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil Questions: 1-How to clinically approach metastatic gastric cancer in terms of molecular biomarkers? 2-What is the best sequence treatment for advanced gastric cancer? 3-How to approach the second line and beyond in advanced gastric cancer? 4-Perspectives of the ICI combinations for advanced gastric...

Expert: Ilaria Colombo, Oncology Institute of Southern Switzerland, Bellinzona, CH Questions: 1-Which is the mechanism of action of PARP inhibitors and why this is relevant in ovarian cancer? 2-How can we measure the homologous recombination deficiency? 3-Which is the current evidence for the use of maintenance PARP inhibitors in recurrent epithelial ovarian cancer? 4-Can you tell us which are the...

Expert: Christos Sotiriou, Institute Jules Bordet, Bruxelles, BE Questions: 1-How do you define clinician-scientists?  2-In 2014 Baumal et al reported  that the number of clinician-scientists has decreased ,do you think this is the case in 2021 too?    -if yes could you elaborate on reasons behind graduates opting out of this option  3-Are mentors determining the path...

Expert: Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona, CH Questions: 1-How drug-drug interactions can be defined? 2-How frequent they are? 3-Can you make some examples with new drugs approved for lymphoid malignancies? 4-Do all new drugs have the same risk of interactions? 5-What is the best management?

Expert: Ramon Andrade Bezerra de Mello, Sao Paulo, Brazil Questions: 1-Stage 3 colon cancer did operation and competed adj chemo (capeox) . after 1 year developed single lung lesion, resection done but the margin was positive!, radiotherapy could not  be given due  to unmarking of resection site, we gave her same adj chemo, after 4 month from completion if chemo developed wide spread dz...

Expert: Elisa Gobbini, Gustave Roussy Institute, Villejuif, FR Questions: 1-What is the role of immunotherapy in PD-L1 negative mNSCLC? 2-Could you describe the rational for cases with negative PDL1 responding to immunotherapy? 3-What about liquid PDL-1 assay and how to be implemented in clinical practice? 4-How long the duration required for re-exposition to previously received immunotherapy? 5-P...

Expert: Giancarlo Pruneri, National Cancer Institute - IRCCS Foundation, Milan, Italy Questions:  1-Can You explain what is meant by the title „low positive“ luminal breast cancer?  2-Is that treshold (<10%) uniform everywhere, in the entire oncology /pathology/ community? 3-What are the guidelines to follow on this question?  4-Can You comment on the two tresholds for defining p...

Expert: Ines Vaz-Luis , Gustave Roussy Institute, Villejuif, France Questions: 1-Alleviating hot flashes on hormonal therapy (including complimentary medicine). 2-Bone targeting agents in patients on adjuvant hormonal therapy (calcium and vitamin D, bisphosphonates, denosumab). 3-Treatment of neuropathy (after taxanes or platinum agents). 4-Alleviating neurocognitial disorders.

Expert: Richard Anderson, University of Edinburgh, Edinburgh, UK Questions: 1- Frequency of fertility loss (in men and women) after most often chemotherapy regimens used in young patients with cancer (ABVD, BEACOPPesc, others, targeted therapies). 2- Effectiveness of ovarian function suppression by GnRH analogues in women as a means of fertility preservation. 3- Effectiveness of various fertility...

Expert: Nadia Harneck, Breast Center, LMU University Hospital, Munich, Germany Questions: 1.The best hormonal partner: evidence on fulvestrant, letrozole or anastrozole. 2.Possibility to use CDK4/6i+AI in mBC in patients progressing during or after completion of adjuvant AI treatment. 3.Ways of overcoming haematologic toxicities (neutropenia, leucopenia). 4.Any evidence on choosing between three d...

Expert: Paolo Bossi , University of Brescia, ASST Spedali Civili, Brescia, Italy Questions: 1-Is there a role for induction chemotherapy for head and neck squamous cell carcinoma other than laryngeal preservation? 2-Could we use weekly cisplatin instead of high-dose three-weekly cisplatin concomitantly with radiotherapy? 3-Do you prefer cetuximab or carboplatin for chemoradiotherapy in patients in...

Expert: Wendy McInally , Open University Edinburgh, United Kingdom 1-Is Melanoma (skin cancer) common in young people across the globe? 2-What are the main signs and symptoms for young people and/or the family to look out for? 3-How is melanoma in young people diagnosed? 4-What is the treatment for melanoma in young people? 5-Where are young people ‘normally’ treated and cared for?

Expert: Tanja Cufer , Medical Faculty, University of Ljubljana, Ljubljana, Slovenia Questions: 1-What are the first baby steps recent oncology graduates can take to advance their international career? 2-If ones country doesn’t provide proper training in conducting research what do you suggest for substitution? 3-Is it advisable(plausable) to take a break from clinics to do research abroad? 4-Can o...

Expert: Michael Gnant, Comprehensive Cancer Center Vienna, Vienna, Austria Questions: 1.What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients?  2.What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)?  3.What is the recommendation for use of denosumab in eBC?  4.What are the data...

Expert: Rosa Di Micco , San Raffaele University and Research Hospital, Milan, Italy Questions: 1-Is pathological sampling mandatory? 2-If positive, it imply in axillary dissection? 3-If clinically LN+ is possible to perform only asentinel lymph node biopsy at surgery?

Expert: Nicholas Pavlidis , University of Ioannina, Ioannina, Greece Questions: 1-What do we know about CUP? 2-What do we know about the impact of genomic analysis in CUP diagnosis and treatment? 3-What standard diagnostic work-up is recommended to have completed, before a case can be called a CUP case?  4-Does speeding up the diagnostic process help patients’ outcome? 5-How doctors transfer...

Expert: Stein Kaasa , Oslo University Hospital, Oslo, NO Questions: 1-Who should be a part of the palliative care team? 2-When to switch palliative care to cancer patients' care? 3-The impact of COVID-19 pandemic on palliative care? 4-How to improve palliative care quality in developing countries? 5-New methods of pain control.

Expert: Joana Ribeiro , Champalimaud Clinical Center, Lisbon, Portugal 1-Define breast cancer with NE differentiation and distinguish it from NEC 2-Discuss neuroendocrine differentiation as an independent adverse prognostic factor for shorter OS / DFS 3-Discuss Ki 67and differentiation between NET / NEC and OS / DFS 4-Discuss adjuvant treatment-  according to the same recommendations given fo...

Expert: Luca Bertolaccini ,  European Institute of Oncology, Milan, Italy 1-What is a systematic review_meta analysis 2-What is the clinical question that needs to be answered 3-How to perform a correct search strategy 4-How to perform the study selection 5-How to perform the statistical analysis